Vorinostat Completed Phase 2 Trials for Graft Versus Host Disease (GVHD) / Neoplasms, Hematologic / Non-Neoplastic Hematologic and Lymphocytic Disorder Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT01790568Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant